|

Opdivo® Clinical Trials

5 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: Nivolumab

Pipeline

Phase 1: 2Phase 2: 2Phase 3: 1

Top Sponsors

  • Shanghai Henlius Biotech2
  • Shandong Boan Biotechnology Co., Ltd1
  • Ono Pharmaceutical Co., Ltd.1
  • Maria Sklodowska-Curie National Research Institute of Oncology1

Indications

  • Cancer5
  • Esophageal and/or Cardia Cancer1
  • Liver Disease1
  • Urothelial Carcinoma (UC)1
  • Nasopharyngeal Cancer1

Other3 trials

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Phase 1
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Phase 2

Phoenix, Arizona1 trial

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Mayo Clinic Arizona

Phase 2

Glendale, California1 trial

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.